Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study
暂无分享,去创建一个
John Seibyl | Ana M Catafau | Henryk Barthel | Kenji Ishii | Christopher C Rowe | James B Leverenz | Bernardino Ghetti | James W Ironside | Masaki Takao | Hiroyasu Akatsu | Shigeo Murayama | Santiago Bullich | Andre Mueller | Norman Koglin | Walter J Schulz-Schaeffer | Anja Hoffmann | Marwan N Sabbagh | Andrew W Stephens | Osama Sabri | C. Rowe | M. Sabbagh | J. Seibyl | B. Ghetti | K. Ishii | W. Schulz-Schaeffer | O. Sabri | H. Barthel | J. Ironside | S. Murayama | J. Leverenz | A. Catafau | M. Takao | N. Koglin | H. Akatsu | S. Bullich | Anja Hoffmann | A. Stephens | A. Mueller
[1] John Seibyl,et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.
[2] Masanori Ichise,et al. PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.
[3] Toshiki Uchihara,et al. Silver diagnosis in neuropathology: principles, practice and revised interpretation , 2007, Acta Neuropathologica.
[4] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[5] R. Boellaard. Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.
[6] W. Kukull,et al. Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.
[7] Charles Duyckaerts,et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.
[8] H. Gertz,et al. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[9] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[10] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[11] L. Dinkelborg,et al. Piramal Imaging. , 2015, Neurodegenerative disease management.
[12] Swen Hesse,et al. Influence of scan duration on the accuracy of β-amyloid PET with florbetaben in patients with Alzheimer’s disease and healthy volunteers , 2012, European Journal of Nuclear Medicine and Molecular Imaging.